We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Taiwanese Upstart Emerges As Threat To Biovail's Wellbutrin XL Patent

Law360 (November 17, 2004, 12:00 AM EST) -- Canadian drug maker Biovail Corp. is bracing itself for a legal battle against upstart Taiwanese drug maker Anchen Pharmaceuticals Inc. over patent rights to blockbuster once-daily antidepressant Wellbutrin XL.

Earlier this week, Biovail said Anchen had submitted an abbreviated new drug application (ANDA) to the U.S. Food and Drug Administration (FDA) for the drug, known generically as bupropion.

Two other generics manufacturers, Eon and Impax, have indicated they intend to file similar ANDAs in the near future.

Closely held Anchen was formed two years ago by...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.